Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
Alvotech (NASDAQ: ALVO) has signed an agreement with DNB Carnegie Investment Bank AB to provide liquidity services for its Swedish Depository Receipts (SDRs) trading on Nasdaq Stockholm. Starting May 20, 2025, DNB Carnegie will act as a liquidity provider, continuously quoting prices for Alvotech's SDRs in compliance with Nasdaq Stockholm's minimum requirements. The primary objective is to enhance SDR liquidity and minimize the spread between buying and selling prices.
Alvotech (NASDAQ: ALVO) ha firmato un accordo con DNB Carnegie Investment Bank AB per fornire servizi di liquidità per i suoi Swedish Depository Receipts (SDR) quotati al Nasdaq di Stoccolma. A partire dal 20 maggio 2025, DNB Carnegie agirà come fornitore di liquidità, quotando continuamente i prezzi degli SDR di Alvotech in conformità con i requisiti minimi di Nasdaq Stoccolma. L'obiettivo principale è migliorare la liquidità degli SDR e ridurre al minimo lo spread tra prezzi di acquisto e vendita.
Alvotech (NASDAQ: ALVO) ha firmado un acuerdo con DNB Carnegie Investment Bank AB para proporcionar servicios de liquidez para sus Swedish Depository Receipts (SDR) que cotizan en Nasdaq Estocolmo. A partir del 20 de mayo de 2025, DNB Carnegie actuará como proveedor de liquidez, cotizando continuamente los precios de los SDR de Alvotech en cumplimiento con los requisitos mínimos de Nasdaq Estocolmo. El objetivo principal es mejorar la liquidez de los SDR y minimizar el diferencial entre los precios de compra y venta.
Alvotech (NASDAQ: ALVO)는 DNB Carnegie Investment Bank AB와 스톡홀름 나스닥에서 거래되는 스웨덴 예탁증서(SDR)에 대한 유동성 서비스를 제공하기 위한 계약을 체결했습니다. 2025년 5월 20일부터 DNB Carnegie는 유동성 공급자로서 나스닥 스톡홀름의 최소 요건을 준수하며 Alvotech SDR의 가격을 지속적으로 제시할 예정입니다. 주요 목표는 SDR의 유동성을 향상시키고 매수와 매도 가격 간의 스프레드를 최소화하는 것입니다.
Alvotech (NASDAQ : ALVO) a signé un accord avec DNB Carnegie Investment Bank AB pour fournir des services de liquidité pour ses Swedish Depository Receipts (SDR) négociés sur le Nasdaq Stockholm. À partir du 20 mai 2025, DNB Carnegie agira en tant que fournisseur de liquidité, en cotant continuellement les prix des SDR d'Alvotech conformément aux exigences minimales du Nasdaq Stockholm. L'objectif principal est d'améliorer la liquidité des SDR et de réduire au minimum l'écart entre les prix d'achat et de vente.
Alvotech (NASDAQ: ALVO) hat eine Vereinbarung mit DNB Carnegie Investment Bank AB unterzeichnet, um Liquiditätsdienste für seine Swedish Depository Receipts (SDRs), die an der Nasdaq Stockholm gehandelt werden, bereitzustellen. Ab dem 20. Mai 2025 wird DNB Carnegie als Liquiditätsanbieter fungieren und kontinuierlich Preise für Alvotechs SDRs unter Einhaltung der Mindestanforderungen der Nasdaq Stockholm stellen. Das Hauptziel ist es, die Liquidität der SDRs zu verbessern und die Spanne zwischen Kauf- und Verkaufspreisen zu minimieren.
- None.
- None.
REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider services to ensure liquidity in the Company’s Swedish Depository Receipts (“SDRs”), equity share equivalents, trading on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm’s rules on liquidity providers.
In the role of liquidity provider, DNB Carnegie undertakes to continuously quote prices for Alvotech’s SDRs in accordance with the applicable minimum requirements for liquidity providers set out by Nasdaq Stockholm. The purpose is to ensure liquidity in the SDRs and reduce the spread between the buying and selling price.
DNB Carnegie’s assignment commences May 20, 2025.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab), are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (U.S.), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, U.K. and U.S.), Biogaran (France), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of products and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
What is the purpose of Alvotech (ALVO) appointing DNB Carnegie as liquidity provider?
When does DNB Carnegie begin its liquidity provider services for Alvotech (ALVO)?
What are the responsibilities of DNB Carnegie as Alvotech's liquidity provider?
Where will Alvotech's SDRs be traded with DNB Carnegie as liquidity provider?
